Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Kovacs

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Stroke|May 21, 2011
Letter by Kovacs regarding article, "Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association"Michael J Kovacs
Archives of Internal Medicine|March 5, 2002
Timing of hypercoagulable screensMichael J Kovacs
Journal of Thrombosis and Thrombolysis|February 14, 2006
The standard is still the standard or why an INR of 2-3 is still the optimal intensity for secondary prevention of venous thromboembolismMichael J Kovacs
Blood|October 25, 2008
MGUS: not so benign after allMichael J Kovacs
ACP Journal Club|May 5, 2004
D-dimer levels < 250 ng/mL after oral anticoagulation predicted a low risk for recurrent venous thromboembolismMichael J Kovacs
The Annals of Pharmacotherapy|April 24, 2003
Autoimmune thrombocytopenia due to chronic lymphocytic leukemia treated with fludarabineTiffany Wells, Michael J Kovacs
The Annals of Pharmacotherapy|April 24, 2003
Cutaneous dalteparin reactions associated with antibodies of heparin-induced thrombocytopeniaSonja M Payne, Michael J Kovacs
Clinical Advances in Hematology & Oncology : H&O|February 24, 2006
Standard-intensity vs low-dose anticoagulation for long-term management of patients with venous thromboembolismAlejandro Lazo-Langner, Michael J Kovacs
Journal of Thrombosis and Haemostasis : JTH|July 30, 2021
APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation: COMMENTMichael J Kovacs, Alejandro Lazo-Langner
Current Opinion in Pulmonary Medicine|May 18, 2010
Predicting warfarin doseAlejandro Lazo-Langner, Michael J Kovacs
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Stroke|May 21, 2011
Letter by Kovacs regarding article, "Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association"Michael J Kovacs
Archives of Internal Medicine|March 5, 2002
Timing of hypercoagulable screensMichael J Kovacs
Journal of Thrombosis and Thrombolysis|February 14, 2006
The standard is still the standard or why an INR of 2-3 is still the optimal intensity for secondary prevention of venous thromboembolismMichael J Kovacs
Blood|October 25, 2008
MGUS: not so benign after allMichael J Kovacs
ACP Journal Club|May 5, 2004
D-dimer levels < 250 ng/mL after oral anticoagulation predicted a low risk for recurrent venous thromboembolismMichael J Kovacs
The Annals of Pharmacotherapy|April 24, 2003
Autoimmune thrombocytopenia due to chronic lymphocytic leukemia treated with fludarabineTiffany Wells, Michael J Kovacs
The Annals of Pharmacotherapy|April 24, 2003
Cutaneous dalteparin reactions associated with antibodies of heparin-induced thrombocytopeniaSonja M Payne, Michael J Kovacs
Clinical Advances in Hematology & Oncology : H&O|February 24, 2006
Standard-intensity vs low-dose anticoagulation for long-term management of patients with venous thromboembolismAlejandro Lazo-Langner, Michael J Kovacs
Journal of Thrombosis and Haemostasis : JTH|July 30, 2021
APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation: COMMENTMichael J Kovacs, Alejandro Lazo-Langner
Current Opinion in Pulmonary Medicine|May 18, 2010
Predicting warfarin doseAlejandro Lazo-Langner, Michael J Kovacs
Pageof 11